These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 39351737

  • 1. Clinical Significance of Faecal Calprotectin in Differentiating Inflammatory Bowel Disease from Irritable Bowel Syndrome.
    Chowdhury MFK, Ghosh CK, Miah MSA, Uddin MA, Rassell M, Rashid MH, Pal AK, Mahabub-Uz-Zaman K, Saha KP, Miah MAR.
    Mymensingh Med J; 2024 Oct; 33(4):1149-1156. PubMed ID: 39351737
    [Abstract] [Full Text] [Related]

  • 2. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
    Waugh N, Cummins E, Royle P, Kandala NB, Shyangdan D, Arasaradnam R, Clar C, Johnston R.
    Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
    [Abstract] [Full Text] [Related]

  • 3. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
    Chang MH, Chou JW, Chen SM, Tsai MC, Sun YS, Lin CC, Lin CP.
    Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
    [Abstract] [Full Text] [Related]

  • 4. Semiquantitative fecal calprotectin test in postinfectious and non-postinfectious irritable bowel syndrome: cross-sectional study.
    David LE, Surdea-Blaga T, Dumitrascu DL.
    Sao Paulo Med J; 2015 Jul; 133(4):343-9. PubMed ID: 26039537
    [Abstract] [Full Text] [Related]

  • 5. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
    Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Rueffer A, Dobos GJ, Roth J, Foell D.
    Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
    [Abstract] [Full Text] [Related]

  • 6. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics.
    Oyaert M, Trouvé C, Baert F, De Smet D, Langlois M, Vanpoucke H.
    Clin Chem Lab Med; 2014 Mar; 52(3):391-7. PubMed ID: 24114912
    [Abstract] [Full Text] [Related]

  • 7. Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome.
    Däbritz J, Musci J, Foell D.
    World J Gastroenterol; 2014 Jan 14; 20(2):363-75. PubMed ID: 24574706
    [Abstract] [Full Text] [Related]

  • 8. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation.
    Fu Y, Wang L, Xie C, Zou K, Tu L, Yan W, Hou X.
    Sci Rep; 2017 Jun 01; 7(1):2669. PubMed ID: 28572616
    [Abstract] [Full Text] [Related]

  • 9. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
    Sydora MJ, Sydora BC, Fedorak RN.
    J Crohns Colitis; 2012 Mar 01; 6(2):207-14. PubMed ID: 22325175
    [Abstract] [Full Text] [Related]

  • 10. Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome.
    Campbell JP, Zierold C, Rode AM, Blocki FA, Vaughn BP.
    J Clin Gastroenterol; 2021 Mar 01; 55(3):239-243. PubMed ID: 32324678
    [Abstract] [Full Text] [Related]

  • 11. Systematic review with meta-analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults.
    Dajti E, Frazzoni L, Iascone V, Secco M, Vestito A, Fuccio L, Eusebi LH, Fusaroli P, Rizzello F, Calabrese C, Gionchetti P, Bazzoli F, Zagari RM.
    Aliment Pharmacol Ther; 2023 Dec 01; 58(11-12):1120-1131. PubMed ID: 37823411
    [Abstract] [Full Text] [Related]

  • 12. A combination of fecal calprotectin and human beta-defensin 2 facilitates diagnosis and monitoring of inflammatory bowel disease.
    Gacesa R, Vich Vila A, Collij V, Mujagic Z, Kurilshikov A, Voskuil MD, Festen EAM, Wijmenga C, Jonkers DMAE, Dijkstra G, Fu J, Zhernakova A, Imhann F, Weersma RK.
    Gut Microbes; 2021 Dec 01; 13(1):1943288. PubMed ID: 34313538
    [Abstract] [Full Text] [Related]

  • 13. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome.
    Otten CM, Kok L, Witteman BJ, Baumgarten R, Kampman E, Moons KG, de Wit NJ.
    Clin Chem Lab Med; 2008 Dec 01; 46(9):1275-80. PubMed ID: 18597588
    [Abstract] [Full Text] [Related]

  • 14. Faecal calprotectin: current usage and perceived beneficial effects of third-party funding on rates of colonoscopy by Australian gastroenterologists.
    Elnawsra O, Fok I, Sparrow M, Gibson P, Andrews J, Connor S.
    Intern Med J; 2016 May 01; 46(5):590-5. PubMed ID: 26946938
    [Abstract] [Full Text] [Related]

  • 15. Role of Calprotectin, IL-6, and CRP in Distinguishing Between Inflammatory Bowel Disease and Diarrhea Predominant Irritable Bowel Syndrome.
    Huong BT, Hien NM, Dung NT, Quang DM, Vinh NT, Tu TT, Chi TK, Phuong LB, Nhan NT.
    Med Arch; 2024 May 01; 78(2):105-111. PubMed ID: 38566874
    [Abstract] [Full Text] [Related]

  • 16. The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity.
    Diederen K, Hoekman DR, Hummel TZ, de Meij TG, Koot BG, Tabbers MM, Vlieger AM, Kindermann A, Benninga MA.
    Aliment Pharmacol Ther; 2016 Jul 01; 44(2):181-8. PubMed ID: 27110920
    [Abstract] [Full Text] [Related]

  • 17. Faecal calprotectin: a new marker for Crohn's disease?
    Wassell J, Dolwani S, Metzner M, Losty H, Hawthorne A.
    Ann Clin Biochem; 2004 May 01; 41(Pt 3):230-2. PubMed ID: 15117438
    [Abstract] [Full Text] [Related]

  • 18. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
    Hoekman DR, Zeevenhooven J, D'Haens GR, Benninga MA.
    Eur J Gastroenterol Hepatol; 2017 Sep 01; 29(9):1086-1090. PubMed ID: 28639969
    [Abstract] [Full Text] [Related]

  • 19. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
    Silberer H, Küppers B, Mickisch O, Baniewicz W, Drescher M, Traber L, Kempf A, Schmidt-Gayk H.
    Clin Lab; 2005 Sep 01; 51(3-4):117-26. PubMed ID: 15819166
    [Abstract] [Full Text] [Related]

  • 20. Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease.
    Gracie DJ, Williams CJ, Sood R, Mumtaz S, Bholah MH, Hamlin PJ, Ford AC.
    Clin Gastroenterol Hepatol; 2017 Mar 01; 15(3):376-384.e5. PubMed ID: 27189912
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.